Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer
CompanyDrug

Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer

Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer
CompanyDrug

Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer

CompanyDrug

Fosun Secures FDA Approval for Two Denosumab Biosimilar Formulations

Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977
CompanyDrug

Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977

Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China
CompanyDrug

Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China

ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies
CompanyDeals

ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies

Sino Biopharmaceutical’s Benmelstobart‑Anlotinib Combo Secures NMPA NDA for Advanced ASPS
CompanyDrug

Sino Biopharmaceutical’s Benmelstobart‑Anlotinib Combo Secures NMPA NDA for Advanced ASPS

Hansoh Pharma Secures Second FDA‑Approved Indication for Inebilizumab in IgG4‑Related Disease
CompanyDrug

Hansoh Pharma Secures Second FDA‑Approved Indication for Inebilizumab in IgG4‑Related Disease

Sanofi’s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP
Others

Sanofi’s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP

Eli Lilly & JD Health Form Digital Care Alliance for Obesity, Diabetes, and Alopecia
CompanyDeals

Eli Lilly & JD Health Form Digital Care Alliance for Obesity, Diabetes, and Alopecia

Gilead’s Seladelpar Approved for PBC Treatment in Beijing Pilot Zone
CompanyDrug

Gilead’s Seladelpar Approved for PBC Treatment in Beijing Pilot Zone

Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402
CompanyDrug

Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402